PEDIATRICS Vol. 27 No. 1 January 1961, pp. 103-111
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sidbury, J. B.
Right arrow Articles by House, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sidbury, J. B., Jr.
Right arrow Articles by House, E.

GLYCOGEN IN ERYTHROCYTES OF PATIENTS WITH GLYCOGEN STORAGE DISEASE

James B. Sidbury Jr. M.D.1, Marvin Cornblath M.D.1, Jean Fisher A.B.1, and Evelyn House B.S.1

1 Department of Pediatrics, Johns Hopkins University School of Medicine, Harriet Lane Home, Johns Hopkins Hospital, and Sinai Hospital, Baltimore

The erythrocyte glycogen concentration has been determined in 63 normal persons and 18 patients with glycogen storage disease. Erythrocyte glycogen from normal patients and from those with glycogenosis has been isolated and characterized by beta-amylase degradation and the iodine spectrum.

By these techniques patients with Type III glycogenosis could be distinguished both by the concentration of glycogen in the erythrocyte and characterization of the glycogen. One patient with amylo-1,4rarr1,6-transglucosidase deficiency (Type IV) was found to have a normal concentration of glycogen in the erythrocytes but the glycogen from the cellular elements of the blood was shown to be abnormal, being amylopectin-like in structure. The concentration of glycogen in the erythrocytes of Types I and II glycogenosis was found to be within the normal range.

The etiologic diagnosis can be made in approximately 50% of the patients with glycogenosis by assay of the concentration and characterization of erythrocyte glycogen, thereby obviating the necessity for biopsy. The erythrocyte glycogen in Type III glycogenosis offers another parameter which may be followed in evaluating the response of the patient to therapy.